A Multi-Center Double-Blind Parallel-Group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation.

Trial Profile

A Multi-Center Double-Blind Parallel-Group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 May 2015

At a glance

  • Drugs Minodronic acid (Primary)
  • Indications Osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 08 Jul 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
    • 08 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 May 2009 Actual patient number (692) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top